---
schema_version: "secwatch.filing_event.v1"
accession: "0001549595-23-000034"
form_type: "8-K"
ticker: "NRIX"
cik: "0001549595"
company_name: "Nurix Therapeutics, Inc."
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T21:50:21.391477+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Nurix shareholders elect all director nominees; say-on-pay passes with 58.5% support

## Summary
- All three Class III directors elected: Sands (97.1%), Kunkel (87.5%), Silva (86.2%) of votes cast.
- Ratification of PricewaterhouseCoopers as auditor received 99.9% of votes cast for.
- Non-binding advisory say-on-pay approval: 19.9M for, 12.5M against, 1.6M abstain (58.5% support).
- Notable 12.5% of votes withheld for Kunkel and 13.8% for Silva, indicating shareholder dissent.

## SEC filing metadata
- accession: 0001549595-23-000034
- form_type: 8-K
- ticker: NRIX
- cik: 0001549595
- company_name: Nurix Therapeutics, Inc.
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549595/000154959523000034/0001549595-23-000034-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549595/000154959523000034/nurix-20230505_8xk2023annu.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001549595-23-000034
- JSON: https://secwatch.observer/filing/0001549595-23-000034.json
- Plain text: https://secwatch.observer/filing/0001549595-23-000034.txt

## Key facts
- Shareholder Votes
  Nurix Therapeutics, Inc. shareholders approved Ratification of appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending November 30, 2023. at the 2023-05-04 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-05-04
  source text: Proposal 2. Ratification of Appointment of Independent Registered Public Accounting Firm Votes For Votes Against Abstentions Broker Non-Votes 39,212,140 10,575 15,196 — The stockholders ratified the appointment
  evidence_url: https://www.sec.gov/Archives/edgar/data/1549595/000154959523000034/0001549595-23-000034-index.htm
- Shareholder Votes
  Nurix Therapeutics, Inc. shareholders approved Election of three Class III directors: Arthur T. Sands, M.D., Ph.D., Lori A. Kunkel, M.D., Paul M. Silva, each to serve a three-year term expiring at the 2026 annual meeting. at the 2023-05-04 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2023-05-04
  source text: Proposal 1. Election of Directors Nominee Votes For Votes Withheld Broker Non-Votes Arthur T. Sands, M.D., Ph.D. 33,080,351 971,642 5,185,918 Lori A. Kunkel, M.D. 29,782,567 4,269,426 5,185,918 Paul M. Silva 29,337,363 4,714,630 5,185,918 Each of the three nominees for director was elected
  evidence_url: https://www.sec.gov/Archives/edgar/data/1549595/000154959523000034/0001549595-23-000034-index.htm
- Shareholder Votes
  Nurix Therapeutics, Inc. shareholders approved Approval, on a non-binding advisory basis, of the compensation of the Company's named executive officers. at the 2023-05-04 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2023-05-04
  source text: Proposal 3. Approval, on a Non-binding Advisory Basis, of the Compensation of the Company’s Named Executive Officers Votes For Votes Against Abstentions Broker Non-Votes 19,907,448 12,499,830 1,644,715 5,185,918 The stockholders approved
  evidence_url: https://www.sec.gov/Archives/edgar/data/1549595/000154959523000034/0001549595-23-000034-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.